Core Insights - The Oncology Institute, Inc. (TOI) reported strong financial results for Q3 2025, with consolidated revenue of $136.6 million, a 36.7% increase from $99.9 million in Q3 2024, and a net loss of $16.5 million compared to a net loss of $16.1 million in the prior year [3][4][20] - The company updated its full-year 2025 guidance, raising revenue expectations to between $495 million and $505 million, while Adjusted EBITDA guidance was adjusted to a loss of $11 million to $13 million [3][4] - TOI's fee-for-service revenue grew by 13% year-over-year, driven by organic growth in Florida and Oregon, and the retail pharmacy and dispensary segment set records with $75.9 million in revenue [4][5] Financial Performance - Consolidated revenue for Q3 2025 was $136.6 million, up from $99.9 million in Q3 2024, while gross profit increased to $18.9 million, a 31.7% rise [4][20] - The net loss for Q3 2025 was $16.5 million, slightly higher than the $16.1 million loss in Q3 2024, with basic and diluted loss per share improving to $(0.14) from $(0.18) [4][20] - Adjusted EBITDA for Q3 2025 was $(3.5) million, an improvement from $(8.2) million in Q3 2024 [4][20] Operational Highlights - The company signed several new in-network MSO providers in Florida and opened a new pharmacy location in the state [4][5] - TOI welcomed Kristin England as the new Chief Administrative Officer, focusing on enterprise operations and technology strategy [4][5] - The company reported a total of 80 clinics and 22 markets, maintaining the number of lives under value-based contracts at approximately 1.9 million [4][17] Guidance and Outlook - TOI expects Adjusted EBITDA of approximately $0 to $2 million in Q4 2025, reflecting a positive outlook for the remainder of the year [3][4] - The updated guidance for 2025 reflects the company's confidence in achieving revenue and profitability growth, despite potential risks in the operating environment [3][4]

Core Insights - The Oncology Institute, Inc. (TOI) reported a strong start to 2025, with expectations for sustained cash flow positivity and profitability in the second half of the year, driven by operational efficiencies and strategic market expansion [4][5][6] - The company anticipates adding approximately $50 million in new revenue from new capitation contracts projected for the first half of 2025, with a potential increase of 100,000 lives in the second half of the year [4][6] Recent Operational Highlights - TOI achieved consolidated revenue of $104.4 million in Q1 2025, a 10.3% increase from $94.7 million in Q1 2024 [8] - The retail pharmacy and dispensary segment generated $49.3 million in revenue, growing over 20% year-over-year [6][9] - Fee-for-service revenue grew by 9% in Q1 2025 compared to Q4 2024, reflecting investments in referral management and call center expansion [6] Financial Performance - Gross profit for Q1 2025 was $17.2 million, a 44.1% increase from the prior year quarter [10] - The net loss for Q1 2025 was $19.6 million, slightly improved from a net loss of $19.9 million in Q1 2024 [12] - Adjusted EBITDA improved to $(5.1) million in Q1 2025 from $(10.9) million in Q1 2024 [12][20] Guidance for Fiscal Year 2025 - TOI expects full-year revenue to be between $460 million and $480 million, with gross profit projected between $73 million and $82 million [7] - The company anticipates Adjusted EBITDA to range from $(8) million to $(17) million for the year [7] Key Business Metrics - As of March 31, 2025, TOI operated 81 clinics across 18 markets, serving approximately 1.9 million lives under value-based contracts [32] - Cash and cash equivalents stood at $39.7 million as of March 31, 2025, down from $49.7 million at the end of 2024 [33]